DMAC(DMAC)
DMAC
ANALYST COVERAGE6 analysts
BUY
▲ +40.8%upside to target
L $7.00
Med $8.00consensus
H $10.00PRICE
Prev Close
6.06
Open
6.05
Day Range5.61 – 6.12
5.61
6.12
52W Range3.48 – 10.42
3.48
10.42
32% of range
VOLUME & SIZE
Avg Volume
195.2K
FUNDAMENTALS
P/E Ratio
-8.0x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Beta
0.54
Low vol
TECHNICAL
RSI (14)
34
Bearish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 20
DEx-Dividend
In 90 days
Aug 17
PDividend Pay
In 97 days
Aug 24
Key MetricsTTM
Market Cap$306.06M
Revenue TTM$0.00
Net Income TTM-$35.10M
Free Cash Flow-$31.09M
Gross Margin0.0%
Operating Margin0.0%
Net Margin0.0%
Return on Equity-77.1%
Return on Assets-66.1%
Debt / Equity0.00
Current Ratio9.11
EPS TTM$-0.65
DMAC News
About
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing novel treatments to improve the lives of patients with neurological and chronic kidney diseases.
Dietrich John PaulsPresident, Chief Executive Officer & Director
Dominic R. CundariChief Commercial Officer
Scott KellenChief Financial Officer & Corporate Secretary
Ambarish ShahChief Technology Officer
Julie KropChief Medical Officer